Jan 6, 2009 - arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency's Committee for Orphan Medicinal Products adopted a positive opinion recommending the company's product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product to the European Commission.
The details can be read here.
No comments:
Post a Comment